NYSE · Medical - Devices

Bio-Rad Laboratories, Inc. (BIO) Stock

$366.16 +1.60% NYSE: BIO Healthcare

Valuation

MetricValue
Price$366.16
Market Cap$9.86B
P/E Ratio44.31
P/B Ratio1.38
P/S Ratio3.84
EPS (TTM)$0.00
52-Week High$396.23
52-Week Low$236.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE3.15%
ROA2.17%
ROCE2.53%
Gross Margin10.45%
Operating Margin10.49%
Net Margin8.59%
Debt/Equity0.17
Current Ratio5.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.9B$2.8B$2.7B$2.6B$2.6B
Operating Profit$500.0M$483.0M$338.0M$269.0M$271.0M
Net Profit$4.3B$-3.6B$-637.0M$-1.8B$760.0M
EPS$140.83$-121.79$-21.82$-65.36$27.87
Op Margin17.1%17.2%12.7%10.5%10.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$17.8B$13.5B$12.3B$9.4B$10.6B
Total Liabilities$4.1B$3.9B$3.6B$2.8B$3.1B
Cash$471.0M$434.0M$404.0M$488.0M$532.0M
Borrowings$223.0M$1.4B$1.4B$1.4B$1.5B

Latest News

BIO: Raising target price to $313.00 Argus Research · Jul 15, 2026 Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) GlobeNewswire · Jun 29, 2026 Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) GlobeNewswire · Jun 24, 2026 Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? Motley Fool · Jun 22, 2026 Global Fluorescent In Situ Hybridization Probe Market Size/Share Worth USD 2.27 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) GlobeNewswire · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$669.0M$194.0M$375.0M$455.0M$532.0M
Investing Cash Flow$-931.0M$-1.3B$-136.0M$-349.0M$-347.0M
Financing Cash Flow$-52.0M$-212.0M$-425.0M$-218.0M$-298.0M
Net Cash Flow$-196.0M$-37.0M$-30.0M$85.0M$40.0M
Free Cash Flow$536.0M$80.0M$218.0M$266.0M$375.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.15
EV / EBITDA19.87
FCF Yield3.55%
Quick Ratio2.33
Interest Coverage6.40
Return 1Y21.80%
Return 3Y0.31%
Return 5Y-49.57%

Ownership

Insiders Held16.34%
Institutions Held94.45%
Institutions Float Held112.90%
Institutional HolderSharesReport Date
First Eagle Investment Management, LLC2,602,7722026-03-31
Blackrock Inc.1,680,0602026-03-31
Dimensional Fund Advisors LP1,089,3232026-03-31
Vanguard Capital Management LLC831,1652026-03-31
Vanguard Portfolio Management LLC829,1862026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTAAzenta, Inc. $37.72 +4.78% -14.09 $1.74B 0.00%
BRKRBruker Corporation $58.84 +1.59% -91.36 $8.96B 0.31%
DHRDanaher Corporation $219.87 +1.11% 39.76 $154.57B 0.71%
LABStandard BioTools Inc. $0.69 +2.85% -3.23 $269.87M 0.00%
MRVIMaravai LifeSciences Holdings, Inc. $7.44 +3.19% -14.75 $2.06B 0.00%

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is led by CEO Norman D. Schwartz, employs 7,450 people, headquartered in Hercules, US, publicly traded since 1980.

Bio-Rad Laboratories, Inc. (BIO) stock trades at $366.16 with a market capitalization of $9.86B. The stock is valued at a price-to-earnings (P/E) ratio of 44.31, price-to-book of 1.38, price-to-sales of 3.84. Over the past 52 weeks the stock has ranged between $236.73 and $396.23, and currently trades 7.6% below its 52-week high.

On profitability, Bio-Rad Laboratories, Inc. generates a return on equity (ROE) of 3.15%, return on capital employed of 2.53%, an operating margin of 10.49%, a net profit margin of 8.59%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides